IL247550B - Sialylated glycoprotein compositions and uses thereof - Google Patents

Sialylated glycoprotein compositions and uses thereof

Info

Publication number
IL247550B
IL247550B IL247550A IL24755016A IL247550B IL 247550 B IL247550 B IL 247550B IL 247550 A IL247550 A IL 247550A IL 24755016 A IL24755016 A IL 24755016A IL 247550 B IL247550 B IL 247550B
Authority
IL
Israel
Prior art keywords
sialyl
glycoprotein composition
glycoprotein
composition
Prior art date
Application number
IL247550A
Other languages
English (en)
Hebrew (he)
Other versions
IL247550A0 (en
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of IL247550A0 publication Critical patent/IL247550A0/en
Publication of IL247550B publication Critical patent/IL247550B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL247550A 2014-03-05 2016-08-30 Sialylated glycoprotein compositions and uses thereof IL247550B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461948421P 2014-03-05 2014-03-05
US201562114313P 2015-02-10 2015-02-10
PCT/US2015/018859 WO2015134696A1 (en) 2014-03-05 2015-03-05 Sialylated glycoprotein compositions and uses thereof

Publications (2)

Publication Number Publication Date
IL247550A0 IL247550A0 (en) 2016-11-30
IL247550B true IL247550B (en) 2020-10-29

Family

ID=54016314

Family Applications (1)

Application Number Title Priority Date Filing Date
IL247550A IL247550B (en) 2014-03-05 2016-08-30 Sialylated glycoprotein compositions and uses thereof

Country Status (17)

Country Link
US (9) US9457067B2 (enExample)
EP (1) EP3113781B1 (enExample)
JP (1) JP6581590B2 (enExample)
KR (1) KR102150481B1 (enExample)
CN (1) CN106102749B (enExample)
AU (1) AU2015227137B2 (enExample)
BR (1) BR112016019893B1 (enExample)
CA (1) CA2940318C (enExample)
ES (1) ES2704923T3 (enExample)
IL (1) IL247550B (enExample)
MX (1) MX368972B (enExample)
MY (1) MY188028A (enExample)
PE (1) PE20161417A1 (enExample)
PH (1) PH12016501658A1 (enExample)
RU (1) RU2689119C2 (enExample)
TW (1) TWI702049B (enExample)
WO (1) WO2015134696A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016019893B1 (pt) 2014-03-05 2023-02-14 Ultragenyx Pharmaceutical Inc Composição
US12391907B2 (en) 2017-12-13 2025-08-19 Neogen Food Safety Us Holdco Corporation Water-reconstitutable culture medium resistant to liquefaction by microorganisms
TWI667252B (zh) * 2018-07-13 2019-08-01 中原大學 阿伐-選擇性唾液酸供體及其於製備唾液酸苷的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
ES2285188T3 (es) * 2002-07-15 2007-11-16 Immunex Corporation Metodo y medios para controlar sialilacion de proteinas producidas por celulas de mamifero.
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
EP1818395A1 (en) * 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
EP2428225A3 (en) * 2006-09-10 2012-05-09 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
WO2008109677A2 (en) * 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
KR101241322B1 (ko) * 2010-02-08 2013-03-11 한국과학기술원 시알산 함량이 높은 재조합 당단백질의 제조 방법
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101457514B1 (ko) * 2011-11-21 2014-11-03 한국생명공학연구원 우렁쉥이(멍게) 유래의 시알산 전이효소 및 이를 이용한 시알화 복합당질 합성 방법
US10138474B2 (en) * 2012-08-17 2018-11-27 Research Foundation Of The City University Of New York Scavenger receptor uptake for fabry disease enzyme replacement therapy
BR112016019893B1 (pt) 2014-03-05 2023-02-14 Ultragenyx Pharmaceutical Inc Composição

Also Published As

Publication number Publication date
US20190054153A1 (en) 2019-02-21
US20240245759A1 (en) 2024-07-25
EP3113781A4 (en) 2017-08-09
US9457068B2 (en) 2016-10-04
JP6581590B2 (ja) 2019-09-25
BR112016019893A2 (pt) 2017-10-24
US20160367646A1 (en) 2016-12-22
AU2015227137A1 (en) 2016-09-15
CA2940318C (en) 2020-09-22
US20170326210A1 (en) 2017-11-16
US20200282028A1 (en) 2020-09-10
MX368972B (es) 2019-10-23
US20150250860A1 (en) 2015-09-10
PE20161417A1 (es) 2017-01-22
US9457067B2 (en) 2016-10-04
BR112016019893B1 (pt) 2023-02-14
CN106102749B (zh) 2019-07-12
IL247550A0 (en) 2016-11-30
ES2704923T3 (es) 2019-03-20
MY188028A (en) 2021-11-10
WO2015134696A1 (en) 2015-09-11
PH12016501658A1 (en) 2016-10-03
MX2016011416A (es) 2016-12-02
RU2016138790A3 (enExample) 2018-08-23
US9937243B2 (en) 2018-04-10
AU2015227137B2 (en) 2019-06-06
US20150366951A1 (en) 2015-12-24
EP3113781A1 (en) 2017-01-11
RU2689119C2 (ru) 2019-05-24
CA2940318A1 (en) 2015-09-11
TWI702049B (zh) 2020-08-21
US20220202915A1 (en) 2022-06-30
KR20160127124A (ko) 2016-11-02
US20260077025A1 (en) 2026-03-19
US9687532B2 (en) 2017-06-27
JP2017508455A (ja) 2017-03-30
CN106102749A (zh) 2016-11-09
KR102150481B1 (ko) 2020-09-02
TW201615210A (zh) 2016-05-01
RU2016138790A (ru) 2018-04-09
EP3113781B1 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
EP3285633A4 (en) STEERING MICROENDOSCOPE
EP3205103C0 (en) INTER AND INTRA UNIFICATION BLOCK COPY
ME03558B (me) Molekuli anti-lag-3 antiтela i njihove upotrebe
DK3137843T3 (da) Projektil med forbedret ballistik
SG11201606624WA (en) Antibody moleules to dengue virus and uses thereof
HUE055473T2 (hu) Difluormetil-aminopiridinek és difluormetil-aminopirimidinek
DK3130649T3 (da) Haloolefin-baseret sammensætning
FR3024363B1 (fr) Composition thermogelifiable
IL237993B (en) Integrating pixels and methods of operation
IL258856A (en) Solabegron zwitterion and uses thereof
PL3207149T3 (pl) Kompozycja farmaceutyczna o zwiększonej stabilności
CL2017000639A1 (es) Composición
PT3337506T (pt) Combinações e suas utilizações
HUE070090T2 (hu) Összetétel
DK3209889T3 (da) Forbedringer i eller angående forbindelsesindretninger
DK3193936T3 (da) Antimikrobielle midler med forøget virkning
IL247550B (en) Sialylated glycoprotein compositions and uses thereof
DK3217964T3 (da) Sammensætning
FR3019552B1 (fr) Composition filmogene
EP3493682C0 (en) COMPOSITION COMPRISING DUDDINGTONIA FLAGRANS
FR3021029B1 (fr) Carenage aerodynamique
FI10663U1 (fi) Järjestely verhopäällystyksen yhteydessä
IL258181A (en) Modified t-cells having anti-fugetactic properties and uses thereof
TH1601002073A (th) องค์ประกอบเครื่องสำอางที่มีความทึบแสงเพิ่มขึ้น

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed